Key Takeaways
- All-around outperformance, guidance raised: Gross margin expanded 320 bps for FY24, the company turned net cash positive, and FY25 operating EBITDA margin guidance was revised up to 26%–28%.
- Domestic + CDMO now the structural core: These two segments grew to 67% of revenue (vs 55% in FY21), driving a mix-led improvement in margins and ROCE, which reached 27%.
- Ophthalmology integration is on track and dilutive: The acquired portfolio is growing, but will be a ~50 bps drag on EBITDA margins in FY25, a headwind management expects to offset with other levers.
- CDMO is entering a new growth phase: European market entry and a US project nearing commercialization support a 12%–14% growth guide, with high teens expected from Q3 onward based on the order book.
- What to watch next quarter: Whether the CDMO ramp materializes on schedule from October, the trajectory of the acute business after a muted season, and any stabilization in Azmarda’s market share.
Domestic Business & Brand Performance
- Outperformance engine: The domestic business will continue to outperform the Indian Pharmaceutical Market by 200 bps, driven by chronic portfolio strength, field productivity, and new product launches.
- Chronic portfolio milestone: The chronic portfolio surpassed INR 1,000 crores, making J.B. the 8th-ranked and fastest-growing company in the cardiology market as of March 2024.
- Top brand strength: The five biggest brands (Rantac, Metrogyl, Cilacar, Cilacar T, Nicardia) rank among the top 150 in the industry, while the Sporlac franchise grew at a 33% CAGR over three years.
- MR productivity gains: Productivity per medical representative nearly doubled in four years to ₹7 lakhs per month and is expected to grow 8%–10% further without any field force additions.
- Acute business recovery bet: Last year was impacted by a muted season, but trends suggest the season will be much better this year, requiring a guided approach.
- Azmarda under pressure: Competitive intensity increased after the LOE event, putting market share under stress, though volumes and value have steadied over the last four months. Management expects the market to consolidate among the top 4–5 players.
Chopra: "The objective of sharing this data of the last 3 years... is more to share with colleagues on the call is how J. B. as a company, J. B. Pharma as a company has progressed over the last 3 years consistently, not only in terms of top line, but, overall, in EBITDA, in profits and also in net working capital and operating cash flow."
Ophthalmology Portfolio Integration
- Seamless transition: The portfolio acquired from Novartis was integrated in January 2024 with strong support from the seller, and products are seeing good uptake after entering J.B.’s commercial DNA.
- Field force ramp: The team has grown to 104 medical representatives with pan-India coverage, addressing close to ₹2,800 crores of the ₹4,000 crores ophthal market across glaucoma, pain, antibiotic, and anti-allergic segments.
- Growth ambition: Management aspires to grow the ophthal portfolio faster than the 14% market growth rate in FY25, targeting a monthly revenue run rate of ₹15–16 crores.
- Portfolio expansion plans: The company may enter dry eyes and antioxidants for ophthalmology, and is evaluating mid-to-long-term in-licensing or partnering for biologics.
Chopra: "We would also like to expand our portfolio in the coming time in the world of dry eyes, where the portfolio is not there and antioxidants for ophthalmology. We may get into mid to long-term in-licensing partnering for some biologics in the world of ophthalmology."
CDMO Business & Growth Levers
- European market entry: The CDMO segment entered Europe with consumer players in immunity and cough/cold lozenges, contributing to 9% YoY growth in Q4.
- Capacity in place: Investments over the last year have resolved packaging bottlenecks, with annualized capacity of 200 crore lozenges now running at a 100 crore run rate.
- New product pipeline: Melatonin-based lozenges are expected to begin commercializing in Q1 FY25, with branded lozenges available in the US market by year-end at a very small scale.
- US project nearing commercialization: One of a couple of US projects is likely to be commercialized soon, though management declined to comment on batch order quantities or scale-up potential, calling it too early.
- $100 million aspiration intact: The CDMO business has almost doubled since FY21, and the $100 million revenue aspiration remains a 3–5 year journey, with newer initiatives starting from October FY24.
Chopra: "You too also understand that this business has got high gestation period. It takes time for any new lozenges to being commercialized because the way it works with the reference sample."
International Business Restructuring
- South Africa strategic shift: The top line was impacted by a deliberate choice to lower tender business and emphasize the private market, whose contribution has risen from 40% to 70% over three years. Profitability improvement was already visible in H2 FY24.
- Russia profitability turnaround: Significant profitability improvement was achieved this year through front-end optimization and a favorable product mix for CIS markets, with similar trends expected to continue.
- Export growth muted at ~6%: The headline number reflects South Africa challenges; excluding South Africa, international business showed 15% growth.
- FY25 export outlook: Double-digit growth expected, with emerging markets and CDMO at 12%–14% and Russia, South Africa, and the US at 8%–9%.
Margins & Profitability
- Gross margin expansion: Cost optimization and favorable product mix drove gross margin expansion of 130 bps in Q4 and 320 bps for FY24.
- Q4 other expenses spike: Higher other expenses were driven by three factors: one-off integration impact, one-off costs incurred during the quarter, and a seasonally soft March for the domestic business, plus a nominal Red Sea freight impact. Management declined to quantify the one-offs.
- Ophthal margin dilution: The acquired portfolio will dilute gross margins by ~150 bps and EBITDA margins by ~50 bps in FY25 and FY26, a headwind management plans to offset through product mix improvement, efficiency programs, and South Africa/Russia margin recovery.
- Margin levers identified: Improving product mix toward chronic, efficiency programs (field productivity, larger bed sizes, vendor management), and South Africa business improvement will all contribute to maintaining the guided 26%–28% operating EBITDA margin.
- Balance sheet strength: Gross debt reduced from INR 548 cr to INR 357 cr, the company turned net cash positive, and operating cash flow more than doubled to INR 801 cr, with cash flow as a percentage of EBITDA improving to 85% from 56%.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating EBITDA margin | 26% to 28% (raised from 25%–27%) | FY25 |
| Overall revenue growth (ex-ophthal) | 12% to 14% | FY25 |
| Domestic business outperformance | Outperform IPM by 200 bps | Ongoing |
| CDMO growth | 12% to 14%, accelerating to high teens | FY25, with high teens from Q3 onward |
| Ophthal monthly revenue run rate | ₹15–16 crores | Target for FY25 |
| Gross margin | Closer to 65% | Coming 2 years |
| EBITDA growth | 16% to 18% | FY25 |
| Domestic + CDMO revenue share | 75% to 80% of overall business | Midterm |
| CDMO revenue aspiration | $100 million | 3–5 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹862 cr, +13% YoY |
| FY24 revenue | ₹3,484 cr, +11% YoY |
| Revenue growth excluding South Africa | +17% in Q4, +14% in FY24 |
| Gross profit margin | 65.2%, expanded 130 bps YoY |
| FY24 gross profit margin | 66.1%, expanded 320 bps YoY |
| Operating EBITDA (excl. ESOP cost) | ₹210 cr, +16% YoY |
| FY24 operating EBITDA (excl. ESOP cost) | ₹939 cr, +23% YoY |
| Operating EBITDA margin guidance | 26% to 28%, revised upward from 25%–27% |
| Domestic business revenue | ₹465 cr, +22% YoY |
| Domestic business FY24 revenue | ₹1,897 cr, +16% YoY |
| International business revenue | ₹397 cr, +4% YoY reported; +15% excluding South Africa |
| CDMO revenue | ₹109 cr, +9% YoY |
| CDMO FY24 revenue | ₹432 cr |
| CDMO as a share of international business | 27%, up from 21% in FY21 |
| MR productivity | ₹7 lakhs per month per medical rep, expected to grow 8%–10% |
| IPM growth vs J.B. growth | 10% for J.B. vs 7.6% industry, IQVIA MAT March 2024 |
| Sporolac franchise revenue | ₹122 cr, 33% CAGR over 3 years, IQVIA MAT March 2024 |
| Azmarda revenue | ₹75 cr |
| Razel growth | +24% YoY |
| Ophthalmology acquisition month-on-month growth | +11% in March 2024, IQVIA |
| Cilacar volume growth | +10% in FY24, IQVIA |
| Cilacar T volume growth | +10% in FY24, IQVIA |
| Nicardia volume growth | +5% in FY24, IQVIA |
| Razel volume growth | +22% in FY24, IQVIA |
| Chronic portfolio revenue | Surpassed ₹1,000 cr, MAT March 2024 |
| South Africa private business contribution | 70%, up from 40% three years ago |
| Operating cash flow FY24 | ₹801 cr, more than doubled from ₹315 cr in FY21 |
| Operating cash flow as a percentage of operating EBITDA | 85%, up from 56% in FY21 |
| Net working capital | 87 days, reduced from 98 days three years ago |
| ROCE | 27% in FY24, up from 21% in FY23 |
| Gross debt | ₹357 cr as of 31 March 2024, down from ₹548 cr a year ago |
| Net cash position | Net cash positive as of March 2024 |
| CDMO lozenges capacity | 200 cr lozenges annualized; current run rate 100 cr lozenges |
| Ophthalmology MR count | 104, ramped from ~75 at acquisition |
| New product contribution to overall growth | 3% |
| Ophthal business monthly revenue run rate target | ₹15 cr to ₹16 cr |
| ESOP cost expected for FY25 | ~₹40 cr |
| Azmarda market share | 14% to 15% |
| Ophthal portfolio gross margin dilution | ~150 bps dilutive |
| Ophthal portfolio EBITDA margin dilution | ~50 bps dip expected in FY25 and FY26 |
| Overall company top line growth guidance (excl. ophthal) | 12% to 14% |
| India, CDMO, and ROW growth guidance | 12% to 14% |
| US, Russia, South Africa growth guidance | High single digit, around 8% to 9% |
| CDMO revenue aspiration | $100 mn, journey for next 3 to 5 years |
| Ophthalmology market size in India | Close to ₹4,000 cr, growing at 14% |
| Acquired ophthal portfolio covered market | Close to ₹2,800 cr |
| Gross margin outlook for coming 2 years | Closer to 65% |